Paolo Tarantino: Looking forward to join the Medscape symposium to review treatment landscape for HR+/HER2- metastatic breast cancer

Paolo Tarantino shared a post on LinkedIn:

“Really looking forward to joining this Medscape symposium to review the evolving treatment landscape for HR+/HER2- metastatic breast cancer.

If you’re attending ESMO24 and are interested in breast oncology, please join us!”

Additional information

Source: Paolo Tarantino/LinkedIn

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.